MX2018009860A - Anticuerpos para il-17c. - Google Patents

Anticuerpos para il-17c.

Info

Publication number
MX2018009860A
MX2018009860A MX2018009860A MX2018009860A MX2018009860A MX 2018009860 A MX2018009860 A MX 2018009860A MX 2018009860 A MX2018009860 A MX 2018009860A MX 2018009860 A MX2018009860 A MX 2018009860A MX 2018009860 A MX2018009860 A MX 2018009860A
Authority
MX
Mexico
Prior art keywords
antibodies
antibody fragments
psoriasis
humans
human
Prior art date
Application number
MX2018009860A
Other languages
English (en)
Inventor
Klattig Jürgen
Ernest René Vandeghinste Nick
Dominik Haas Jan
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2018009860A publication Critical patent/MX2018009860A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona anticuerpos o fragmentos de anticuerpo que se unen a IL-17C humana. En particular, se refiere a anticuerpos o fragmentos de anticuerpo que tienen propiedades beneficiosas combinadas y por lo tanto, son útiles para el tratamiento de seres humanos que tienen, por ejemplo, dermatitis atópica o psoriasis.
MX2018009860A 2016-02-19 2017-02-17 Anticuerpos para il-17c. MX2018009860A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16156582 2016-02-19
EP16156651 2016-02-22
PCT/EP2017/053592 WO2017140831A1 (en) 2016-02-19 2017-02-17 Antibodies for il-17c

Publications (1)

Publication Number Publication Date
MX2018009860A true MX2018009860A (es) 2019-03-28

Family

ID=58057136

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009860A MX2018009860A (es) 2016-02-19 2017-02-17 Anticuerpos para il-17c.

Country Status (34)

Country Link
US (5) US20190048071A1 (es)
EP (1) EP3416983B1 (es)
JP (2) JP6535139B2 (es)
KR (1) KR102715157B1 (es)
CN (1) CN108699143B (es)
AU (1) AU2017219837B2 (es)
BR (1) BR112018016798A2 (es)
CA (1) CA3014842A1 (es)
CL (1) CL2018002340A1 (es)
CO (1) CO2018008724A2 (es)
CU (1) CU20180087A7 (es)
CY (1) CY1124296T1 (es)
DK (1) DK3416983T3 (es)
EA (1) EA037813B1 (es)
EC (1) ECSP18070641A (es)
ES (1) ES2877376T3 (es)
HR (1) HRP20211059T1 (es)
HU (1) HUE054755T2 (es)
IL (1) IL260733B2 (es)
LT (1) LT3416983T (es)
MA (2) MA44227B1 (es)
MD (1) MD3416983T2 (es)
MX (1) MX2018009860A (es)
PE (1) PE20181648A1 (es)
PH (1) PH12018501739A1 (es)
PL (1) PL3416983T3 (es)
RS (1) RS62012B1 (es)
SG (1) SG11201806161TA (es)
SI (1) SI3416983T1 (es)
SM (1) SMT202100361T1 (es)
TN (1) TN2018000289A1 (es)
TW (1) TW201734041A (es)
WO (1) WO2017140831A1 (es)
ZA (1) ZA201806249B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018114657A (ru) * 2015-10-05 2019-11-07 МорфоСис АГ Антагонисты IL-17C для лечения и/или предупреждения атопического дерматита
CA3014842A1 (en) * 2016-02-19 2017-08-24 Morphosys Ag Antibodies for il-17c
EP3688031A1 (en) * 2017-09-25 2020-08-05 MorphoSys AG Treatment of atopic dermatitis
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
TW202011995A (zh) 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
US20220411465A1 (en) * 2019-11-22 2022-12-29 Morphosys Ag Eluate collection during antibody chromatography
WO2021099536A1 (en) * 2019-11-22 2021-05-27 Morphosys Ag Method to increase antibody yield during ion exchange chromatography

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
ES2292242T5 (es) * 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
CA2347973C (en) 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
KR20070084330A (ko) 2004-10-18 2007-08-24 지모제넥틱스, 인코포레이티드 가용성 ｚｃｙｔｏｒ21, 항-ｚｃｙｔｏｒ21 항체 및 결합파트너 및 염증에서의 사용방법
WO2007047738A1 (en) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
CA2666842A1 (en) 2006-10-18 2008-04-24 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
EP3214442A1 (en) * 2010-10-25 2017-09-06 F. Hoffmann-La Roche AG Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a
EP2640742B1 (en) 2010-11-19 2018-08-15 MorphoSys AG A collection of antibody sequences its use
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP2768859B1 (en) * 2011-10-19 2018-02-21 MorphoSys AG Antagonists of il17c for the treatment of inflammatory disorders
WO2013186236A1 (en) 2012-06-12 2013-12-19 Orega Biotech Antagonists of il-17 isoforms and their uses
EP3233915B1 (en) * 2014-12-15 2024-08-28 MorphoSys AG Antibodies for il-17c
CA3014842A1 (en) * 2016-02-19 2017-08-24 Morphosys Ag Antibodies for il-17c

Also Published As

Publication number Publication date
MA44227A (fr) 2018-12-26
MA44227B1 (fr) 2021-06-30
EA037813B1 (ru) 2021-05-24
US10259869B2 (en) 2019-04-16
DK3416983T3 (en) 2021-06-21
WO2017140831A1 (en) 2017-08-24
AU2017219837B2 (en) 2023-08-17
BR112018016798A2 (en) 2018-12-26
US10633439B2 (en) 2020-04-28
IL260733B2 (en) 2024-03-01
KR20180109977A (ko) 2018-10-08
CN108699143A (zh) 2018-10-23
CU20180087A7 (es) 2019-03-04
US20250074978A1 (en) 2025-03-06
US20190048071A1 (en) 2019-02-14
EP3416983B1 (en) 2021-04-07
SI3416983T1 (sl) 2021-08-31
EP3416983A1 (en) 2018-12-26
US20200216529A1 (en) 2020-07-09
JP2019511910A (ja) 2019-05-09
ZA201806249B (en) 2020-02-26
HUE054755T2 (hu) 2021-09-28
MA43088B1 (fr) 2020-10-28
SMT202100361T1 (it) 2021-07-12
CL2018002340A1 (es) 2018-11-23
LT3416983T (lt) 2021-07-12
MD3416983T2 (ro) 2021-08-31
KR102715157B1 (ko) 2024-10-10
US20180340024A1 (en) 2018-11-29
CO2018008724A2 (es) 2018-08-31
SG11201806161TA (en) 2018-08-30
US20190202906A1 (en) 2019-07-04
ECSP18070641A (es) 2018-10-31
PE20181648A1 (es) 2018-10-15
JP6916834B2 (ja) 2021-08-11
MA43088A1 (fr) 2019-05-31
TW201734041A (zh) 2017-10-01
ES2877376T3 (es) 2021-11-16
IL260733B1 (en) 2023-11-01
CY1124296T1 (el) 2022-11-25
PH12018501739A1 (en) 2019-06-10
JP2019162119A (ja) 2019-09-26
PL3416983T3 (pl) 2021-10-25
TN2018000289A1 (en) 2020-01-16
IL260733A (es) 2018-09-20
AU2017219837A1 (en) 2018-08-09
HRP20211059T1 (hr) 2021-10-01
EA201891594A1 (ru) 2019-01-31
US11987621B2 (en) 2024-05-21
CN108699143B (zh) 2021-11-09
CA3014842A1 (en) 2017-08-24
RS62012B1 (sr) 2021-07-30
JP6535139B2 (ja) 2019-06-26

Similar Documents

Publication Publication Date Title
PH12018501739A1 (en) Antibodies for il-17c
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12019502755A1 (en) Antibodies that specifically bind pd-1 and methods of use
PH12019502283A1 (en) Anti-lag3 antibodies
PH12019501533A1 (en) Tigit-and light-based chimeric proteins
PH12019500929A1 (en) Anti il-33 antibodies and uses thereof
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MY198562A (en) Antibodies specifically binding pd-1 and their uses
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MY186352A (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
PH12016501820A1 (en) Il-21 antibodies
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
MX2022006575A (es) Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.
ZA201807816B (en) Anti-il-22r antibodies
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
ZA201900070B (en) Antibodies with low immunogenicity and uses thereof
ZA202006216B (en) Antibodies targeting glycoprotein vi
MX376061B (es) Anticuerpos contra antìgeno de plaqueta 1a humano (hpa-1a).